Protalix outlines 2026 rare-disease growth and pipeline strategy

Protalix ( (PLX) ) has shared an update.

On January 5, 2026, Protalix BioTherapeutics released a letter to stockholders outlining its strategy to build a growing, profitable rare-disease business anchored by commercial partnerships and an expanding pipeline. Management highlighted solid 2025 commercial execution with partner Chiesi for Elfabrio in Fabry disease, with patient metrics and market share in the U.S., EU and other markets tracking to plan, and reiterated expectations that Elfabrio could capture 15–20% of a global Fabry market projected at about $3.4 billion by 2030. The company noted that a re-examination of the European regulator’s November 2025 negative opinion on an every‑four‑weeks Elfabrio dosing regimen is underway, with an appeal decision expected in the first quarter of 2026, while the existing bi‑weekly label remains unaffected. Protalix also pointed to steady, durable revenue contributions from Elelyso through its partnerships with Pfizer and Brazil’s Fiocruz as key supports for operating resilience. On the pipeline side, Protalix emphasized PRX‑115 for uncontrolled gout as a potential third commercial molecule, citing Phase 1 data showing rapid, durable urate-lowering with a favorable tolerability profile and the October 2025 U.S. IND clearance enabling a Phase 2 trial with initial sites already activated. In parallel, the company is sharpening its focus on rare kidney diseases, advancing PRX‑119, a long‑acting DNase I candidate targeting inflammation and fibrosis, and pursuing an AI‑enabled RNA-based collaboration with Secarna Pharmaceuticals to develop novel therapies for rare renal indications. Entering 2026, Protalix framed its outlook around three priorities: supporting Chiesi’s Elfabrio commercialization, advancing PRX‑115 in uncontrolled gout, and progressing its rare renal programs, aiming to limit downside risk while preserving meaningful upside for patients, partners and shareholders.

The most recent analyst rating on (PLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Spark’s Take on PLX Stock

According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.

Protalix’s stock score is primarily influenced by its financial performance improvements and positive earnings call highlights. However, technical analysis indicates bearish momentum, and recent corporate events pose regulatory challenges, impacting the overall score.

To see Spark’s full report on PLX stock, click here.

More about Protalix

Protalix BioTherapeutics, based in Carmiel, Israel, is a biopharmaceutical company focused on discovering, developing, producing and commercializing innovative therapies for rare diseases using its proprietary ProCellEx plant cell-based expression system. The company has developed and manufactures two enzyme replacement therapies, including Elelyso for Gaucher disease (licensed globally to Pfizer except in Brazil) and Elfabrio for Fabry disease (developed and commercialized globally with Chiesi), and is the first to secure U.S. FDA approval for a protein produced via a plant cell-based suspension expression system.

Average Trading Volume: 738,071

Technical Sentiment Signal: Sell

Current Market Cap: $139.9M

Learn more about PLX stock on TipRanks’ Stock Analysis page.